Lucas Gabriel Souza Franca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lucas Gabriel Souza Franca has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Dafnis Batalle
Department of Forensic and Neurodevelopmental Science, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
7 shared publications - Grainne Mary McAlonan
Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
5 shared publications - Mario André Leocadio-Miguel
Northumbria University
5 shared publications - Anthony David Edwards
King's College London
4 shared publications - Chiara Nosarti
Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
4 shared publications Shona Falconer
Centre for the Developing Brain, School of Biomedical Engineering & Imaging Sciences, King’s College London, London, UK
4 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by Springer Nature in Translational Psychiatry
Autistic neural ‘shiftability’: the distinct pharmacological landscape of the autistic brain
- 31 August 2026
- Published by Springer Nature in Translational Psychiatry
Open AccessAutistic neural ‘shiftability’: the distinct pharmacological landscape of the autistic brain
- Open Access
Distinct response of resting-state brain networks to psilocybin in autism
Importance There is increasing interest in the potential of psilocybin to treat mental health and neurodevelopmental conditions. At high doses, the therapeutic benefit of psilocybin is linked to greater functional connectivity or integration between large-scale brain networks which underpin mood, emotion and cognition. However, it is unknown how the brain responds to psilocybin in autism - a condition characterised by both altered functional connectivity and differential response to drugs. Thus, a first step before clinical trials of psilocybin involving autistic people, is to evaluate the response of the autistic brain to psilocybin, initially at low dose. Objective Low doses of psilocybin were used to test the hypothesis that the functional connectivity of large-scale resting-state brain networks respond differently in autistic and non-autistic adults. Design The PSILAUT study had a pseudo-randomised, cross-over, double-blind, case-control design. There was no evaluation of clinical efficacy. PSILAUT was not a Clinical Trial according to UK regulations. Data collection was conducted from January 2023 to August 2024. Setting Single-centre, study conducted at the Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, United Kingdom. Participants Adult (> 18 years) participants with and without an autism spectrum disorder (ASD) diagnosis were recruited and matched for age, sex and IQ. Autistic participants were included if they had an existing diagnosis (DSM-IV, DSM-5 or ICD-10 criteria). Exposures A single oral dose of 2 or 5 mg psilocybin or (inactive) placebo administered on separate visits at least one week apart. Main Outcomes and Measures Resting-state fMRI was acquired to investigate the change in functional connectivity within and between brain networks, as measures of network integrity and integration, respectively. Results A total of 67 participants were recruited (18-58 years at first visit; 30 non-autistic participants, mean [SD] age, 30.0 [8.3] years, 15 males [50%] and 37 autistic participants, mean [SD] age, 28.6 [9.2] years, 19 males [51%]). We report for the first time that the autistic brain responds differently to low doses of psilocybin, despite no group differences in network connectivity in the baseline placebo condition. 5 mg psilocybin elicited the greatest shifts in functional connectivity in both groups, but in different directions. In non-autistic participants only, on average, after 5 mg psilocybin within-network connectivity of the frontoparietal (β = -0.053, T = -2.73, FDR-corrected P value = 0.027, Cohen d = -0.71) and limbic networks (β = -0.087, T = -2.59, FDR-corrected P value = 0.021, Cohen d = -0.61) decreased. In contrast, in autistic participants, 5 mg psilocybin increased between-network connectivity (i.e. integration) of higher-order and attentional networks, but decreased connectivity between the same networks in non-autistic participants (default mode and frontoparietal networks, dose x group interaction: β = 0.053, T = 2.91, FDR-corrected P value = 0.042; dorsal and ventral attention networks, dose x group interaction: β = 0.059, T = 2.31, FDR-corrected P value = 0.015). Across the whole sample, the extent to which psilocybin elicited an increase in connectivity between higher-order (β = 0.33, T = 2.16, FDR-corrected P value = 0.036) and attentional (β = 0.36, T = 2.43, FDR-corrected P value = 0.036) networks was positively correlated with core autistic traits quantified using the Autism Quotient. Conclusions and Relevance Functional brain networks that support mood, emotion and cognition are more responsive to low dose psilocybin in autistic adults compared to non-autistic adults. Given that increased network integration is associated with clinical utility, future applications of psilocybin in autistic people should include the evaluation of low doses.
Open AccessDistinct response of resting-state brain networks to psilocybin in autism
Importance There is increasing interest in the potential of psilocybin to treat mental health and neurodevelopmental conditions. At high doses, the therapeutic benefit of psilocybin is linked to greater functional connectivity or integration between large-scale brain networks which underpin mood, emotion and cognition. However, it is unknown how the brain responds to psilocybin in autism - a condition characterised by both altered functional connectivity and differential response to drugs. Thus, a first step before clinical trials of psilocybin involving autistic people, is to evaluate the response of the autistic brain to psilocybin, initially at low dose. Objective Low doses of psilocybin were used to test the hypothesis that the functional connectivity of large-scale resting-state brain networks respond differently in autistic and non-autistic adults. Design The PSILAUT study had a pseudo-randomised, cross-over, double-blind, case-control design. There was no evaluation of clinical efficacy. PSILAUT was not a Clinical Trial according to UK regulations. Data collection was conducted from January 2023 to August 2024. Setting Single-centre, study conducted at the Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, United Kingdom. Participants Adult (> 18 years) participants with and without an autism spectrum disorder (ASD) diagnosis were recruited and matched for age, sex and IQ. Autistic participants were included if they had an existing diagnosis (DSM-IV, DSM-5 or ICD-10 criteria). Exposures A single oral dose of 2 or 5 mg psilocybin or (inactive) placebo administered on separate visits at least one week apart. Main Outcomes and Measures Resting-state fMRI was acquired to investigate the change in functional connectivity within and between brain networks, as measures of network integrity and integration, respectively. Results A total of 67 participants were recruited (18-58 years at first visit; 30 non-autistic participants, mean [SD] age, 30.0 [8.3] years, 15 males [50%] and 37 autistic participants, mean [SD] age, 28.6 [9.2] years, 19 males [51%]). We report for the first time that the autistic brain responds differently to low doses of psilocybin, despite no group differences in network connectivity in the baseline placebo condition. 5 mg psilocybin elicited the greatest shifts in functional connectivity in both groups, but in different directions. In non-autistic participants only, on average, after 5 mg psilocybin within-network connectivity of the frontoparietal (β = -0.053, T = -2.73, FDR-corrected P value = 0.027, Cohen d = -0.71) and limbic networks (β = -0.087, T = -2.59, FDR-corrected P value = 0.021, Cohen d = -0.61) decreased. In contrast, in autistic participants, 5 mg psilocybin increased between-network connectivity (i.e. integration) of higher-order and attentional networks, but decreased connectivity between the same networks in non-autistic participants (default mode and frontoparietal networks, dose x group interaction: β = 0.053, T = 2.91, FDR-corrected P value = 0.042; dorsal and ventral attention networks, dose x group interaction: β = 0.059, T = 2.31, FDR-corrected P value = 0.015). Across the whole sample, the extent to which psilocybin elicited an increase in connectivity between higher-order (β = 0.33, T = 2.16, FDR-corrected P value = 0.036) and attentional (β = 0.36, T = 2.43, FDR-corrected P value = 0.036) networks was positively correlated with core autistic traits quantified using the Autism Quotient. Conclusions and Relevance Functional brain networks that support mood, emotion and cognition are more responsive to low dose psilocybin in autistic adults compared to non-autistic adults. Given that increased network integration is associated with clinical utility, future applications of psilocybin in autistic people should include the evaluation of low doses.
- Open Access
Menstrual cycle irregularity is a biological determinant of mental health independent of sleep in adolescents
INTRODUCTION: Sex differences in mental health emerge during adolescence, a period marked by the onset and the establishment of menstrual cycle. However, is rarely examined how menstrual cycle regularity, a marker of hormonal function, modulates mental health. OBJECTIVE: to analyse sex differences in mental health symptoms among adolescents considering the menstrual cycle regularity and sleep. METHODS: A three-group design (female students with regular cycles/FR, n=77; with irregular cycles/FI, n=59; and male students/M, n=76) in a sample of Brazilian high-school adolescents (n=212; 14–18 years) enrolled in morning and full-time classes was used to test the hypothesis that mental health symptoms follow a graded pattern across these groups. RESULTS: Mean DASS-21 scores across all groups fell at or above the Mild severity threshold for mental health subscales. GLMs confirmed a monotonic gradient increase in group order (M→FR→FI) which was associated with higher scores on all outcomes (stress β/step=4.33, p<.001; anxiety β/step=4.08, p<.001; and depression β/step=2.34, p=.010; model R²=.16, .13, .08 respectively). However, no differences were observed in sleep duration, social jetlag, chronotype, sleep quality, or sleep-debt. Then, a secondary analysis assessed sex-specific associations between socioeconomic status (SES) and mental health; higher SES was inversely related to stress, anxiety, and depression, being protective only in males (stress Males β=−2.68, p=.011/Females β=0.46, p=.614). CONCLUSION: These findings support the reframing of menstrual irregularity not only as a reproductive health concern but also as a biological determinant of mental health risk in female adolescents, a vulnerability that sleep disruption and socioeconomic resources do not adequately explain.
Open AccessMenstrual cycle irregularity is a biological determinant of mental health independent of sleep in adolescents
INTRODUCTION: Sex differences in mental health emerge during adolescence, a period marked by the onset and the establishment of menstrual cycle. However, is rarely examined how menstrual cycle regularity, a marker of hormonal function, modulates mental health. OBJECTIVE: to analyse sex differences in mental health symptoms among adolescents considering the menstrual cycle regularity and sleep. METHODS: A three-group design (female students with regular cycles/FR, n=77; with irregular cycles/FI, n=59; and male students/M, n=76) in a sample of Brazilian high-school adolescents (n=212; 14–18 years) enrolled in morning and full-time classes was used to test the hypothesis that mental health symptoms follow a graded pattern across these groups. RESULTS: Mean DASS-21 scores across all groups fell at or above the Mild severity threshold for mental health subscales. GLMs confirmed a monotonic gradient increase in group order (M→FR→FI) which was associated with higher scores on all outcomes (stress β/step=4.33, p<.001; anxiety β/step=4.08, p<.001; and depression β/step=2.34, p=.010; model R²=.16, .13, .08 respectively). However, no differences were observed in sleep duration, social jetlag, chronotype, sleep quality, or sleep-debt. Then, a secondary analysis assessed sex-specific associations between socioeconomic status (SES) and mental health; higher SES was inversely related to stress, anxiety, and depression, being protective only in males (stress Males β=−2.68, p=.011/Females β=0.46, p=.614). CONCLUSION: These findings support the reframing of menstrual irregularity not only as a reproductive health concern but also as a biological determinant of mental health risk in female adolescents, a vulnerability that sleep disruption and socioeconomic resources do not adequately explain.
- Open Access
- 6 May 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (5) , e0348631
From movement to METs: A validation of ActTrust® for energy expenditure estimation and physical activity classification in young adults
Estimating physical activity (PA) levels is a challenging and expensive task. An alternative could be the use of actigraphy devices to estimate PA. This has been previously done to a number of devices, including ActiGraph® GT3X + . In this study, we validated ActTrust® against the widely used GT3X+ and compared activity counts to metabolic equivalents (METs) derived from indirect calorimetry during treadmill walking and running. Fifty-six young adults (34 men, 22 women) participated in controlled effort exercises including light, moderate, vigorous, and very vigorous activity intensities. We developed a linear model to estimate energy expenditure (EE) from movement count of combinations of devices placed at hip or wrist. We then estimated cut-off points for each intensity range. Our results showed correlations between treadmill speed and both METs ( r = 0.95, p < 0.05) and movement counts from both GT3X+ and ActTrust devices placed either on the hip ( r = 0.94, p < 0.05; r = 0.93, p < 0.05) or on the wrist ( r = 0.88, p < 0.05; r = 0.88, p < 0.05), respectively. Our proposed model performed well with balanced accuracies above 0.77 for all intensity ranges and over 0.9 for light and moderate activity. This is the first study to model estimate and validate PA intensity thresholds on ActTrust® devices. Our findings support the use of ActTrust® devices as simple, cost-effective tool for 24-hour assessments of EE.
- 6 May 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (5) , e0348631
Open AccessFrom movement to METs: A validation of ActTrust® for energy expenditure estimation and physical activity classification in young adults
Estimating physical activity (PA) levels is a challenging and expensive task. An alternative could be the use of actigraphy devices to estimate PA. This has been previously done to a number of devices, including ActiGraph® GT3X + . In this study, we validated ActTrust® against the widely used GT3X+ and compared activity counts to metabolic equivalents (METs) derived from indirect calorimetry during treadmill walking and running. Fifty-six young adults (34 men, 22 women) participated in controlled effort exercises including light, moderate, vigorous, and very vigorous activity intensities. We developed a linear model to estimate energy expenditure (EE) from movement count of combinations of devices placed at hip or wrist. We then estimated cut-off points for each intensity range. Our results showed correlations between treadmill speed and both METs ( r = 0.95, p < 0.05) and movement counts from both GT3X+ and ActTrust devices placed either on the hip ( r = 0.94, p < 0.05; r = 0.93, p < 0.05) or on the wrist ( r = 0.88, p < 0.05; r = 0.88, p < 0.05), respectively. Our proposed model performed well with balanced accuracies above 0.77 for all intensity ranges and over 0.9 for light and moderate activity. This is the first study to model estimate and validate PA intensity thresholds on ActTrust® devices. Our findings support the use of ActTrust® devices as simple, cost-effective tool for 24-hour assessments of EE.
- Open Access
Low-latitude environmental regularity sustains non-photic entrainment in blind adults
The light–dark cycle shaped by Earth’s rotation provided the evolutionary conditions under which circadian rhythms emerged. Consistent with this, previous studies indicate that less than 40% of total blind individuals, who lack photic input, entrain to the 24-h cycle, further evidencing the critical role of light as the dominant zeitgeber for circadian alignment. However, this assumption has been tested almost exclusively in temperate, high-latitude regions, where environmental cues vary seasonally. Near the equator, by contrast, photoperiod and temperature cycles remain exceptionally stable. This highlights a fundamental gap: can circadian rhythms in humans remain synchronised without light when environmental temporal cues are highly regular? We addressed this question in 58 blind adults (21–77 years; 43.1% female) living near the equator in Rio Grande do Norte, Brazil (∼5°S), who wore wrist actigraphy continuously for four weeks. Light sensitivity was assessed through the pupillary light reflex (PLR; 22 PLR-reactive, 36 non-reactive). Applying a semi-supervised machine learning approach to uncover multidimensional patterns without prior categorisation, we identified two distinct phenotypes: a Higher Circadian Stability (HCS; 72%, n = 42) and a Lower Circadian Stability group (LCS; 28%, n = 16). Notably, 64% of PLR-non-reactive individuals (23 of 36) were classified within the HCS group, a proportion approximately 1.6 times higher than previously reported for blind cohorts. These findings demonstrate that, under exceptionally regular equatorial conditions, non-photic cues can sustain a robust circadian entrainment even in the absence of photic input. We propose that environmental regularity promotes the synergy of non-photic timing signals, underscoring ecological context as a key determinant of human circadian temporal organisation.
Open AccessLow-latitude environmental regularity sustains non-photic entrainment in blind adults
The light–dark cycle shaped by Earth’s rotation provided the evolutionary conditions under which circadian rhythms emerged. Consistent with this, previous studies indicate that less than 40% of total blind individuals, who lack photic input, entrain to the 24-h cycle, further evidencing the critical role of light as the dominant zeitgeber for circadian alignment. However, this assumption has been tested almost exclusively in temperate, high-latitude regions, where environmental cues vary seasonally. Near the equator, by contrast, photoperiod and temperature cycles remain exceptionally stable. This highlights a fundamental gap: can circadian rhythms in humans remain synchronised without light when environmental temporal cues are highly regular? We addressed this question in 58 blind adults (21–77 years; 43.1% female) living near the equator in Rio Grande do Norte, Brazil (∼5°S), who wore wrist actigraphy continuously for four weeks. Light sensitivity was assessed through the pupillary light reflex (PLR; 22 PLR-reactive, 36 non-reactive). Applying a semi-supervised machine learning approach to uncover multidimensional patterns without prior categorisation, we identified two distinct phenotypes: a Higher Circadian Stability (HCS; 72%, n = 42) and a Lower Circadian Stability group (LCS; 28%, n = 16). Notably, 64% of PLR-non-reactive individuals (23 of 36) were classified within the HCS group, a proportion approximately 1.6 times higher than previously reported for blind cohorts. These findings demonstrate that, under exceptionally regular equatorial conditions, non-photic cues can sustain a robust circadian entrainment even in the absence of photic input. We propose that environmental regularity promotes the synergy of non-photic timing signals, underscoring ecological context as a key determinant of human circadian temporal organisation.
- Open Access
- 24 June 2025
- Published by SAGE Publications in Neurorehabilitation and Neural Repair
- Vol. 39 (9) , 742-751
Resting-state Alpha Reactivity Is Reduced in Parkinson’s Disease and Associated With Gait Variability
Background: The extent to which the cholinergic system contributes to gait impairments in Parkinson’s disease (PD) remains unclear. Electroencephalography (EEG) alpha reactivity, which refers to change in alpha power over occipital electrodes upon opening the eyes, has been suggested as a marker of cholinergic function. We compared alpha reactivity between people with PD and healthy individuals and explored its potential association with gait measures. Methods: Eyes-closed and eyes-open resting-state EEG data were recorded from 20 people with idiopathic PD and 19 healthy individuals with a 64-channel EEG system. Alpha reactivity was calculated as the relative change in alpha power (8-13 Hz) over occipital electrodes from eyes-closed to eyes-open. Gait spatiotemporal measures were obtained with an electronic walkway. Results: Alpha reactivity was reduced in people with PD compared to healthy individuals ( U = 105, P = .017); the rank-biserial correlation of .447 indicated a moderate effect size. When controlling for global cognition (Mini Mental State Examination), the group difference in alpha reactivity was no longer significant. Alpha reactivity associated with measures of gait variability only (ρ = −.437 to −.532). Conclusions: Resting-state alpha reactivity is reduced in PD, suggesting impaired cholinergic function. Reduced alpha reactivity was associated with greater gait variability, indicating a role of the cholinergic system in the mechanisms underlying gait variability. Therefore, the cholinergic system may represent a target for treatments aiming to reduce gait variability and alpha reactivity should be further explored as an endpoint for clinical trials.
- 24 June 2025
- Published by SAGE Publications in Neurorehabilitation and Neural Repair
- Vol. 39 (9) , 742-751
Open AccessResting-state Alpha Reactivity Is Reduced in Parkinson’s Disease and Associated With Gait Variability
Background: The extent to which the cholinergic system contributes to gait impairments in Parkinson’s disease (PD) remains unclear. Electroencephalography (EEG) alpha reactivity, which refers to change in alpha power over occipital electrodes upon opening the eyes, has been suggested as a marker of cholinergic function. We compared alpha reactivity between people with PD and healthy individuals and explored its potential association with gait measures. Methods: Eyes-closed and eyes-open resting-state EEG data were recorded from 20 people with idiopathic PD and 19 healthy individuals with a 64-channel EEG system. Alpha reactivity was calculated as the relative change in alpha power (8-13 Hz) over occipital electrodes from eyes-closed to eyes-open. Gait spatiotemporal measures were obtained with an electronic walkway. Results: Alpha reactivity was reduced in people with PD compared to healthy individuals ( U = 105, P = .017); the rank-biserial correlation of .447 indicated a moderate effect size. When controlling for global cognition (Mini Mental State Examination), the group difference in alpha reactivity was no longer significant. Alpha reactivity associated with measures of gait variability only (ρ = −.437 to −.532). Conclusions: Resting-state alpha reactivity is reduced in PD, suggesting impaired cholinergic function. Reduced alpha reactivity was associated with greater gait variability, indicating a role of the cholinergic system in the mechanisms underlying gait variability. Therefore, the cholinergic system may represent a target for treatments aiming to reduce gait variability and alpha reactivity should be further explored as an endpoint for clinical trials.
- Open Access
From Movement to METs: A Validation of ActTrust® for Energy Expenditure Estimation and Physical Activity Classification in Young Adults
Estimating physical activity (PA) levels is a challenging and expensive task. An alternative could be the use of actigraphy devices to estimate PA. This has been previously done to a number of devices, including ActiGraph® GT3X+. In this study, we validated ActTrust® against the widely used GT3X+ and compared activity counts to metabolic equivalents (METs) derived from indirect calorimetry during treadmill walking and running. Fifty-six young adults (34 men, 22 women) participated in controlled effort exercises including light, moderate, vigorous, and very vigorous activity intensities. We developed a linear model to estimate energy expenditure (EE) from movement count of combinations of devices placed at hip or wrist. We then estimated cut-off points for each intensity range. Our results showed correlations between treadmill speed and both METs ( r = 0.95, p < 0.05) and movement counts from both GT3X+ and ActTrust devices placed either on the hip ( r = 0.94, p < 0.05; r = 0.93, p < 0.05) or on the wrist ( r = 0.88, p < 0.05; r = 0.88, p < 0.05), respectively. Our proposed model performed well with balanced accuracies above 0.77 for all intensity ranges and over 0.9 for light and moderate activity. This is the first study to model estimate and validate PA intensity thresholds on ActTrust® devices. Our findings support the use of ActTrust® devices as simple, cost-effective tool for 24-hour assessments of EE.
Open AccessFrom Movement to METs: A Validation of ActTrust® for Energy Expenditure Estimation and Physical Activity Classification in Young Adults
Estimating physical activity (PA) levels is a challenging and expensive task. An alternative could be the use of actigraphy devices to estimate PA. This has been previously done to a number of devices, including ActiGraph® GT3X+. In this study, we validated ActTrust® against the widely used GT3X+ and compared activity counts to metabolic equivalents (METs) derived from indirect calorimetry during treadmill walking and running. Fifty-six young adults (34 men, 22 women) participated in controlled effort exercises including light, moderate, vigorous, and very vigorous activity intensities. We developed a linear model to estimate energy expenditure (EE) from movement count of combinations of devices placed at hip or wrist. We then estimated cut-off points for each intensity range. Our results showed correlations between treadmill speed and both METs ( r = 0.95, p < 0.05) and movement counts from both GT3X+ and ActTrust devices placed either on the hip ( r = 0.94, p < 0.05; r = 0.93, p < 0.05) or on the wrist ( r = 0.88, p < 0.05; r = 0.88, p < 0.05), respectively. Our proposed model performed well with balanced accuracies above 0.77 for all intensity ranges and over 0.9 for light and moderate activity. This is the first study to model estimate and validate PA intensity thresholds on ActTrust® devices. Our findings support the use of ActTrust® devices as simple, cost-effective tool for 24-hour assessments of EE.
- Open Access
Resting-state alpha reactivity is reduced in Parkinson’s disease and associated with gait variability
Background: The extent to which the cholinergic system contributes to gait impairments in Parkinson’s disease (PD) remains unclear. Electroencephalography (EEG) alpha reactivity, which refers to change in alpha power over occipital electrodes upon opening the eyes, has been suggested as a marker of cholinergic function. We compared alpha reactivity between people with PD and healthy individuals and explored its potential association with gait measures. Methods: Eyes-closed and eyes-open resting-state EEG data were recorded from 20 people with idiopathic PD and 19 healthy individuals with a 64-channel EEG system. Alpha reactivity was calculated as the relative change in alpha power (8-13 Hz) over occipital electrodes from eyes-closed to eyes-open. Gait spatiotemporal measures were obtained with an electronic walkway. Results: Alpha reactivity was reduced in people with PD compared to healthy individuals (U = 105, p = 0.017); the rank-biserial correlation of 0.447 indicated a moderate effect size. When controlling for global cognition (Mini Mental State Examination), the group difference in alpha reactivity was no longer significant. Alpha reactivity associated with measures of gait variability only (rho = −0.437 to −0.532). Conclusions: Reduced alpha reactivity in PD is driven by levels of global cognition and suggests impaired cholinergic function in PD. Reduced alpha reactivity was associated with greater gait variability, indicating a role of the cholinergic system in the mechanisms underlying gait variability. Therefore, the cholinergic system may represent a target for treatments aiming to reduce gait variability and alpha reactivity should be further explored as an endpoint for clinical trials.
Open AccessResting-state alpha reactivity is reduced in Parkinson’s disease and associated with gait variability
Background: The extent to which the cholinergic system contributes to gait impairments in Parkinson’s disease (PD) remains unclear. Electroencephalography (EEG) alpha reactivity, which refers to change in alpha power over occipital electrodes upon opening the eyes, has been suggested as a marker of cholinergic function. We compared alpha reactivity between people with PD and healthy individuals and explored its potential association with gait measures. Methods: Eyes-closed and eyes-open resting-state EEG data were recorded from 20 people with idiopathic PD and 19 healthy individuals with a 64-channel EEG system. Alpha reactivity was calculated as the relative change in alpha power (8-13 Hz) over occipital electrodes from eyes-closed to eyes-open. Gait spatiotemporal measures were obtained with an electronic walkway. Results: Alpha reactivity was reduced in people with PD compared to healthy individuals (U = 105, p = 0.017); the rank-biserial correlation of 0.447 indicated a moderate effect size. When controlling for global cognition (Mini Mental State Examination), the group difference in alpha reactivity was no longer significant. Alpha reactivity associated with measures of gait variability only (rho = −0.437 to −0.532). Conclusions: Reduced alpha reactivity in PD is driven by levels of global cognition and suggests impaired cholinergic function in PD. Reduced alpha reactivity was associated with greater gait variability, indicating a role of the cholinergic system in the mechanisms underlying gait variability. Therefore, the cholinergic system may represent a target for treatments aiming to reduce gait variability and alpha reactivity should be further explored as an endpoint for clinical trials.
- Open Access
Autistic Neural Shiftability: The Distinct Pharmacological Landscape of the Autistic Brain
Functionally inter-connected large-scale brain networks regulated by multiple neurotransmitter systems underpin complex human behaviour. A wide range of alterations in this neurofunctional landscape have been associated with autism. However, this evidence is mostly derived from cross-sectional analyses and thus assumes that any differences are static. Indeed, large sample sizes are required to identify reproducible baseline differences in functional connectivity between autistic and non-autistic individuals. Instead, we propose that what is different in autism is not necessarily the baseline functional connectivity of resting-state networks, but rather their responsivity or regulation by neurotransmitter systems. We tested this hypothesis using a uniform analytical framework to capture the modulation of functional connectivity by single doses of pharmacological probes targeting three major neurotransmitter systems implicated in autism, namely gamma-amino-butyric-acid (GABA), serotonin (5HT) and mu opioid systems. Every drug challenge altered resting-state network connectivity differentially in the autistic compared to the non-autistic group. However, regardless of the neurotransmitter system probed, drug challenge elicited increases in between-network connectivity in autistic participants but minimal or decreased between-network connectivity in their non-autistic peers. There was no group difference in the responsivity of within-network connectivity. Thus, there is altered responsivity of neurotransmitter systems in the autistic brain. This has important implications for pharmacotherapy in autism because these neurotransmitter systems are the targets of several medications commonly prescribed to manage mental health conditions that frequently co-occur in autism. Investigating if these drug-induced shifts in functional connectivity can help provide better targeted clinical interventions, will be important next translational steps.
Open AccessAutistic Neural Shiftability: The Distinct Pharmacological Landscape of the Autistic Brain
Functionally inter-connected large-scale brain networks regulated by multiple neurotransmitter systems underpin complex human behaviour. A wide range of alterations in this neurofunctional landscape have been associated with autism. However, this evidence is mostly derived from cross-sectional analyses and thus assumes that any differences are static. Indeed, large sample sizes are required to identify reproducible baseline differences in functional connectivity between autistic and non-autistic individuals. Instead, we propose that what is different in autism is not necessarily the baseline functional connectivity of resting-state networks, but rather their responsivity or regulation by neurotransmitter systems. We tested this hypothesis using a uniform analytical framework to capture the modulation of functional connectivity by single doses of pharmacological probes targeting three major neurotransmitter systems implicated in autism, namely gamma-amino-butyric-acid (GABA), serotonin (5HT) and mu opioid systems. Every drug challenge altered resting-state network connectivity differentially in the autistic compared to the non-autistic group. However, regardless of the neurotransmitter system probed, drug challenge elicited increases in between-network connectivity in autistic participants but minimal or decreased between-network connectivity in their non-autistic peers. There was no group difference in the responsivity of within-network connectivity. Thus, there is altered responsivity of neurotransmitter systems in the autistic brain. This has important implications for pharmacotherapy in autism because these neurotransmitter systems are the targets of several medications commonly prescribed to manage mental health conditions that frequently co-occur in autism. Investigating if these drug-induced shifts in functional connectivity can help provide better targeted clinical interventions, will be important next translational steps.
- Open Access
- 2 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0298703
Cycling reduces the entropy of neuronal activity in the human adult cortex
Brain Complexity (BC) have successfully been applied to study the brain electroencephalographic signal (EEG) in health and disease. In this study, we employed recurrence entropy to quantify BC associated with the neurophysiology of movement by comparing BC in both resting state and cycling movement. We measured EEG in 24 healthy adults and placed the electrodes on occipital, parietal, temporal and frontal sites on both the right and left sides of the brain. We computed the recurrence entropy from EEG measurements during cycling and resting states. Entropy is higher in the resting state than in the cycling state for all brain regions analysed. This reduction in complexity is a result of the repetitive movements that occur during cycling. These movements lead to continuous sensorial feedback, resulting in reduced entropy and sensorimotor processing.
- 2 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0298703
Open AccessCycling reduces the entropy of neuronal activity in the human adult cortex
Brain Complexity (BC) have successfully been applied to study the brain electroencephalographic signal (EEG) in health and disease. In this study, we employed recurrence entropy to quantify BC associated with the neurophysiology of movement by comparing BC in both resting state and cycling movement. We measured EEG in 24 healthy adults and placed the electrodes on occipital, parietal, temporal and frontal sites on both the right and left sides of the brain. We computed the recurrence entropy from EEG measurements during cycling and resting states. Entropy is higher in the resting state than in the cycling state for all brain regions analysed. This reduction in complexity is a result of the repetitive movements that occur during cycling. These movements lead to continuous sensorial feedback, resulting in reduced entropy and sensorimotor processing.